Yüklüyor......
P08.65 Evaluation of Clinical Benefit in patients treated with Bevacizumab
OBJECTIVE: Bevacizumab (BV), a monoclonal antibody for the treatment of recurrence of glioblastoma, was approved in 2009 in USA whereas today no such approval there is in the European Union. BV showed a higher response rates and prolongation of median at 6 month progression free survival (PFS) compa...
Kaydedildi:
| Yayımlandı: | Neuro Oncol |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782693/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.198 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|